CDSCO Approves India's First Dengue Vaccine For People Aged 4 To 60
- CDSCO has approved Takeda's Qdenga as India's first dengue vaccine.
- The vaccine is approved for use in individuals aged 4 to 60 years.
- Dengue is endemic in India, with lakhs of cases reported each year.
- The approval follows clinical trials and safety reviews by Indian regulators.
- Public health experts say a national vaccination strategy is now needed.
India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved the country's first dengue vaccine. The shot, developed by Japanese pharmaceutical company Takeda, is cleared for use in people aged 4 to 60.
The decision, reported on Wednesday, ends a long wait for a preventive tool against a disease that sickens lakhs of Indians every year. Dengue is endemic across the country, with outbreaks occurring in both urban and rural areas during and after the monsoon season.
What The Vaccine Offers
Takeda's vaccine, marketed as Qdenga, is a live-attenuated tetravalent vaccine. It targets all four serotypes of the dengue virus. The CDSCO approval follows clinical trials that demonstrated its safety and efficacy in preventing dengue fever and reducing the risk of severe disease.
Unlike some earlier dengue vaccines, which raised concerns about disease enhancement in seronegative individuals, Qdenga has shown a more favorable profile. The drug regulator has cleared it for a broad age range, from young children to older adults.
Public health experts point out that the vaccine's effectiveness varies by serotype and prior exposure. Still, the approval is seen as a breakthrough in India's fight against a mosquito-borne disease that strains the healthcare system every year.
The Dengue Burden In India
India accounts for a significant share of the global dengue burden. According to official data, the country reports lakhs of cases annually, though the actual number is believed to be much higher due to underreporting. The disease causes severe fever, joint pain, and in some cases, hemorrhagic fever and death.
Dengue is primarily transmitted by Aedes mosquitoes, which breed in stagnant water. Outbreaks are common during the monsoon months, from July to October. Hospitals in affected areas often face a surge in admissions, putting pressure on beds and medical staff.
The availability of a vaccine does not mean the end of the problem. Public health officials stress that vector control measures—such as eliminating breeding sites and using mosquito repellents—remain critical.
What Comes Next
The CDSCO approval is only the first step. Now, the government must decide how to deploy the vaccine. Questions about pricing, procurement, and prioritization remain unanswered. Will the vaccine be included in the national immunization program? Will it be targeted at high-burden states or rolled out universally?
The health ministry has not yet announced a vaccination strategy. Experts say a phased approach, starting with regions that report the highest number of cases, might be the most practical. The vaccine's cost and cold-chain requirements will also shape the rollout.
Takeda has not disclosed the price for the Indian market. The company is likely to work with the government and private sector to ensure access. India has a strong track record of vaccine manufacturing, but this is an imported product, which could affect affordability.
For now, the approval gives India a new weapon against dengue. But as with any public health intervention, the real test lies in implementation. The coming months will show whether this vaccine can turn the tide against a disease that has eluded control for decades.